Chiusura precedente | 2,1300 |
Aperto | 2,1500 |
Denaro | 2,0600 x 100 |
Lettera | 2,1700 x 100 |
Min-Max giorno | 2,0200 - 2,2899 |
Intervallo di 52 settimane | 1,4000 - 7,7500 |
Volume | |
Media Volume | 258.583 |
Capitalizzazione | 55,432M |
Beta (5 anni mensile) | 0,05 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,8900 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 14,00 |
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing facility in California LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufac
100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff100% (4/4) overall response rate and 75% (3/4) complete response rate observed in t(11;14) relapsed/refractory AL AmyloidosisBest responder duration of response was 19.2 months with response ongoing; median follow-up of 7.3 months (range: 2.5 – 16.5 months) as of the data cutoff date o
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-of